Recent News & Events
-
2018
-
2017
-
2016
<
>
|
October
18 |
Olatec’s lead compound, dapansutrile, referenced in Clinical Rheumatology publication entitled, “Early canakinumab therapy for the sensorineural deafness in a family with Muckle-Wells syndrome due to a novel mutation of NLRP3 gene”
Read More |
|
August
31 |
Olatec referenced in American Journal of Physiology-Heart and Circulatory Physiology publication entitled, “Inflammasome, Pyroptosis, and Cytokines in Myocardial Ischemia-Reperfusion Injury”
Read More |
|
August
3 |
Olatec manuscript published in Arthritis Research & Therapy entitled, "NLRP3 inflammasome inhibitor OLT1177™ suppresses joint inflammation in murine models of acute arthritis”
Read More |
|
July
20 |
Olatec’s lead compound (OLT1177™ dapansutrile) referenced in Nature publication entitled, "Targeting the NLRP3 inflammasome in inflammatory diseases”
Read More |
|
April
4 |
Olatec referenced in Nature Scientific Reports publication entitled,"Development of a characterised tool kit for the interrogation of NLRP3 inflammasome-dependent responses”
Read More |
|
March
1 |
Charles Dinarello MD, CSO and Chairman of Olatec’s Scientific Advisory Board, presents select data on dapansutrile at the European Crystal Network Workshop in Paris, France.
|
|
February
23 |
Olatec referenced in European Heart Journal, published on behalf of European Society of Cardiology, entitled, "Interleukin-1 blockade in cardiovascular diseases: a clinical update”
Read More |
|
January
29 |
Olatec’s research manuscript published in Proceedings of the National Academy of Sciences, entitled "OLT1177™ , a β‑sulfonyl nitrile compound, safe in humans, inhibits the NLRP3 inflammasome and reverses the metabolic cost of inflammation”.
Read More |
|
January
9 |
Robert Barrow, presents Olatec at Biotech Showcase ™ 2018 in San Francisco, CA. Biotech Showcase ™ is an investor conference during the J.P. Morgan Annual Healthcare Conference, one of the industry's largest annual healthcare investor conferences
|
|
November
16 |
Olatec referenced in Nature Reviews Cardiology entitled, "The NLRP3 inflammasome in acute myocardial infarction”
|
|
November
12 |
Stefano Toldo, PhD, Virginia Commonwealth University Assistant Professor, Department of Internal Medicine Division of Cardiology, presents poster, “Novel NLRP3 Inflammasome Inhibitor OLT1177™ Reduces Infarct Size in a Mouse Model of Myocardial Ischemia Reperfusion Injury” at the AHA conference in Anaheim, CA
|
|
October
11 |
Olatec referenced in Nature Biotechnology entitled, “Novartis trial validates inflammasome as chronic disease driver”
|
|
June
14 |
Carlo Marchetti, PhD, Director for Olatec’s Innovative Science Program in Dr. Charles Dinarello’s Laboratory, presents, “The Human Safe NLRP3 Inflammasome Inhibitor OLT1177™ Suppresses Joint Inflammation in Murine Models of Experimental Arthritis” at EULAR conference in Madrid, Spain
|
|
April
21 |
Carlo Marchetti, PhD, Director for Olatec’s Innovative Science Program in Dr. Charles Dinarello’s Laboratory, presents poster, “The Novel and Safe Pharmaceutical Compound OLT1177™ Reduces Inflammation by Preventing Activation of the NLRP3 inflammasome” at AAP/ASCI/APSA Meeting in Chicago, IL
|
|
March
19 |
Antonio Abbate, MD, PhD joins the Olatec Scientific Advisory Board. Dr. Abbate is a prominent leader in the field of cardiovascular disease
|
|
November
27 |
Franz Hefti, PhD joins the Olatec Scientific Advisory Board. Dr. Hefti is a prominent leader in the development of neurodegenerative therapeutics and an experienced biotech CEO
|